The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
iwCLL 2017 | Autonomous B-Cell Receptor (BCR) signaling in Chronic Lymphocytic Leukemia (CLL)
On 14th May 2017, the “Role of the B-Cell Receptor and Other Signaling Pathways in CLL” took place at iwCLL, and was co-chaired by Nicholas Chiorazzi (The Feinstein Institute for Medical Research, Manhasset, NY, USA) and Kostas Stamatopoulos (Center for Research and Technology Hellas, Thessaloniki, Greece).
“Autonomous BCR Signaling in CLL” was a talk given during this session by Hassan Jumaa, PhD, University of Ulm, Germany.
Hassan Jumaa began the talk by asking is B-Cell Receptor (BCR) expression required for CLL?
Next, it was asked how BCR is activated?
BCRs derived from CLL B-cells are often polyreactive; 3 of 6 tested show polyreactivity. Polyreactivity causes mutual interaction of adjacent BCRs and this interaction can occur in the absence of an exogenous antigen. This kind of BCR activation is cell-autonomous.
Moreover, BCRs from Eµ TCL1 transgenic mice display autonomous signaling. Hassan Jumaa then asked if other lymphoma-derived BCRs also display autonomous signaling? It has been found that BCRs derived from MM, MCL, MZL, and FL do not display autonomous signaling.
However, as mentioned above, not all CLL-derived BCRs are polyreactive. Only 25% (1/4) tested BCRs from Eµ TCL1 transgenic mice display polyreactivity.
The Heavy Chain Complementarity-Determining Region 3 (HCDR3), which is known to play a key role in the binding of monoreactive antibodies to antigens, has been found to interact with intrinsic BCR structures. Different HCDR3 have different interaction partners. The limited amount of BCR-intrinsic structures might explain the restricted repertoire and the stereotypes of HCDR3 regions in CLL (Dühren-von Minden et al. 2012).
References